Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

β-Cell-intrinsic β-arrestin 1 signaling enhances sulfonylurea-induced insulin secretion.

Barella LF, Rossi M, Zhu L, Cui Y, Mei FC, Cheng X, Chen W, Gurevich VV, Wess J.

J Clin Invest. 2019 Jun 11;130. pii: 126309. doi: 10.1172/JCI126309.

2.

A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation.

Sammons RM, Perry NA, Li Y, Cho EJ, Piserchio A, Zamora-Olivares DP, Ghose R, Kaoud TS, Debevec G, Bartholomeusz C, Gurevich VV, Iverson TM, Giulianotti M, Houghten RA, Dalby KN.

ACS Chem Biol. 2019 Jun 21;14(6):1183-1194. doi: 10.1021/acschembio.9b00093. Epub 2019 May 13.

PMID:
31058487
3.

Crystal structure of the SH3 domain of human Lyn non-receptor tyrosine kinase.

Berndt S, Gurevich VV, Iverson TM.

PLoS One. 2019 Apr 10;14(4):e0215140. doi: 10.1371/journal.pone.0215140. eCollection 2019.

4.

Using In Vitro Pull-Down and In-Cell Overexpression Assays to Study Protein Interactions with Arrestin.

Perry NA, Zhan X, Gurevich EV, Iverson TM, Gurevich VV.

Methods Mol Biol. 2019;1957:107-120. doi: 10.1007/978-1-4939-9158-7_7.

PMID:
30919350
5.

Critical role of the finger loop in arrestin binding to the receptors.

Zheng C, Tholen J, Gurevich VV.

PLoS One. 2019 Mar 15;14(3):e0213792. doi: 10.1371/journal.pone.0213792. eCollection 2019.

6.

GPCR Signaling Regulation: The Role of GRKs and Arrestins.

Gurevich VV, Gurevich EV.

Front Pharmacol. 2019 Feb 19;10:125. doi: 10.3389/fphar.2019.00125. eCollection 2019. Review.

7.

Arrestin mutations: Some cause diseases, others promise cure.

Gurevich VV, Gurevich EV.

Prog Mol Biol Transl Sci. 2019;161:29-45. doi: 10.1016/bs.pmbts.2018.09.004. Epub 2018 Oct 24.

PMID:
30711028
8.

The structural basis of the arrestin binding to GPCRs.

Gurevich VV, Gurevich EV.

Mol Cell Endocrinol. 2019 Mar 15;484:34-41. doi: 10.1016/j.mce.2019.01.019. Epub 2019 Jan 28. Review.

PMID:
30703488
9.

Arrestin-mediated signaling: Is there a controversy?

Gurevich VV, Gurevich EV.

World J Biol Chem. 2018 Dec 12;9(3):25-35. doi: 10.4331/wjbc.v9.i3.25. Review.

10.

Arrestin-3 scaffolding of the JNK3 cascade suggests a mechanism for signal amplification.

Perry NA, Kaoud TS, Ortega OO, Kaya AI, Marcus DJ, Pleinis JM, Berndt S, Chen Q, Zhan X, Dalby KN, Lopez CF, Iverson TM, Gurevich VV.

Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):810-815. doi: 10.1073/pnas.1819230116. Epub 2018 Dec 27.

11.

Cleavage of arrestin-3 by caspases attenuates cell death by precluding arrestin-dependent JNK activation.

Kook S, Vishnivetskiy SA, Gurevich VV, Gurevich EV.

Cell Signal. 2019 Feb;54:161-169. doi: 10.1016/j.cellsig.2018.11.023. Epub 2018 Dec 4.

PMID:
30529266
12.

Arrestins: Introducing Signaling Bias Into Multifunctional Proteins.

Gurevich VV, Chen Q, Gurevich EV.

Prog Mol Biol Transl Sci. 2018;160:47-61. doi: 10.1016/bs.pmbts.2018.07.007. Epub 2018 Sep 6.

PMID:
30470292
13.

Arrestins and G proteins in cellular signaling: The coin has two sides.

Gurevich VV, Gurevich EV.

Sci Signal. 2018 Sep 25;11(549). pii: eaav1646. doi: 10.1126/scisignal.aav1646. Review.

14.

Enhanced Mutant Compensates for Defects in Rhodopsin Phosphorylation in the Presence of Endogenous Arrestin-1.

Samaranayake S, Song X, Vishnivetskiy SA, Chen J, Gurevich EV, Gurevich VV.

Front Mol Neurosci. 2018 Jun 18;11:203. doi: 10.3389/fnmol.2018.00203. eCollection 2018.

15.

GPCRs and Signal Transducers: Interaction Stoichiometry.

Gurevich VV, Gurevich EV.

Trends Pharmacol Sci. 2018 Jul;39(7):672-684. doi: 10.1016/j.tips.2018.04.002. Epub 2018 May 5. Review.

16.

Structural Basis of Arrestin-Dependent Signal Transduction.

Chen Q, Iverson TM, Gurevich VV.

Trends Biochem Sci. 2018 Jun;43(6):412-423. doi: 10.1016/j.tibs.2018.03.005. Epub 2018 Apr 7. Review.

17.

Arrestins: structural disorder creates rich functionality.

Gurevich VV, Gurevich EV, Uversky VN.

Protein Cell. 2018 Dec;9(12):986-1003. doi: 10.1007/s13238-017-0501-8. Epub 2018 Feb 16. Review.

18.

Molecular Defects of the Disease-Causing Human Arrestin-1 C147F Mutant.

Vishnivetskiy SA, Sullivan LS, Bowne SJ, Daiger SP, Gurevich EV, Gurevich VV.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):13-20. doi: 10.1167/iovs.17-22180.

19.

Molecular Mechanisms of GPCR Signaling: A Structural Perspective.

Gurevich VV, Gurevich EV.

Int J Mol Sci. 2017 Nov 24;18(12). pii: E2519. doi: 10.3390/ijms18122519. Review.

20.

Heterologous phosphorylation-induced formation of a stability lock permits regulation of inactive receptors by β-arrestins.

Tóth AD, Prokop S, Gyombolai P, Várnai P, Balla A, Gurevich VV, Hunyady L, Turu G.

J Biol Chem. 2018 Jan 19;293(3):876-892. doi: 10.1074/jbc.M117.813139. Epub 2017 Nov 16.

21.

Non-visual arrestins regulate the focal adhesion formation via small GTPases RhoA and Rac1 independently of GPCRs.

Cleghorn WM, Bulus N, Kook S, Gurevich VV, Zent R, Gurevich EV.

Cell Signal. 2018 Jan;42:259-269. doi: 10.1016/j.cellsig.2017.11.003. Epub 2017 Nov 11.

22.

Structural basis of arrestin-3 activation and signaling.

Chen Q, Perry NA, Vishnivetskiy SA, Berndt S, Gilbert NC, Zhuo Y, Singh PK, Tholen J, Ohi MD, Gurevich EV, Brautigam CA, Klug CS, Gurevich VV, Iverson TM.

Nat Commun. 2017 Nov 10;8(1):1427. doi: 10.1038/s41467-017-01218-8.

23.

Using two-site binding models to analyze microscale thermophoresis data.

Tso SC, Chen Q, Vishnivetskiy SA, Gurevich VV, Iverson TM, Brautigam CA.

Anal Biochem. 2018 Jan 1;540-541:64-75. doi: 10.1016/j.ab.2017.10.013. Epub 2017 Oct 18.

24.

Identification of Phosphorylation Codes for Arrestin Recruitment by G Protein-Coupled Receptors.

Zhou XE, He Y, de Waal PW, Gao X, Kang Y, Van Eps N, Yin Y, Pal K, Goswami D, White TA, Barty A, Latorraca NR, Chapman HN, Hubbell WL, Dror RO, Stevens RC, Cherezov V, Gurevich VV, Griffin PR, Ernst OP, Melcher K, Xu HE.

Cell. 2017 Jul 27;170(3):457-469.e13. doi: 10.1016/j.cell.2017.07.002.

25.

Uncovering missing pieces: duplication and deletion history of arrestins in deuterostomes.

Indrischek H, Prohaska SJ, Gurevich VV, Gurevich EV, Stadler PF.

BMC Evol Biol. 2017 Jul 6;17(1):163. doi: 10.1186/s12862-017-1001-4.

26.

Hepatic β-arrestin 2 is essential for maintaining euglycemia.

Zhu L, Rossi M, Cui Y, Lee RJ, Sakamoto W, Perry NA, Urs NM, Caron MG, Gurevich VV, Godlewski G, Kunos G, Chen M, Chen W, Wess J.

J Clin Invest. 2017 Aug 1;127(8):2941-2945. doi: 10.1172/JCI92913. Epub 2017 Jun 26.

27.

A Novel Dominant Mutation in SAG, the Arrestin-1 Gene, Is a Common Cause of Retinitis Pigmentosa in Hispanic Families in the Southwestern United States.

Sullivan LS, Bowne SJ, Koboldt DC, Cadena EL, Heckenlively JR, Branham KE, Wheaton DH, Jones KD, Ruiz RS, Pennesi ME, Yang P, Davis-Boozer D, Northrup H, Gurevich VV, Chen R, Xu M, Li Y, Birch DG, Daiger SP.

Invest Ophthalmol Vis Sci. 2017 May 1;58(5):2774-2784. doi: 10.1167/iovs.16-21341.

28.

Functional role of the three conserved cysteines in the N domain of visual arrestin-1.

Vishnivetskiy SA, Lee RJ, Zhou XE, Franz A, Xu Q, Xu HE, Gurevich VV.

J Biol Chem. 2017 Jul 28;292(30):12496-12502. doi: 10.1074/jbc.M117.790386. Epub 2017 May 23.

29.

Differential manipulation of arrestin-3 binding to basal and agonist-activated G protein-coupled receptors.

Prokop S, Perry NA, Vishnivetskiy SA, Toth AD, Inoue A, Milligan G, Iverson TM, Hunyady L, Gurevich VV.

Cell Signal. 2017 Aug;36:98-107. doi: 10.1016/j.cellsig.2017.04.021. Epub 2017 Apr 28.

30.

Arrestin-2 and arrestin-3 differentially modulate locomotor responses and sensitization to amphetamine.

Zurkovsky L, Sedaghat K, Ahmed MR, Gurevich VV, Gurevich EV.

Neuropharmacology. 2017 Jul 15;121:20-29. doi: 10.1016/j.neuropharm.2017.04.021. Epub 2017 Apr 15.

31.

β-arrestin-2 is an essential regulator of pancreatic β-cell function under physiological and pathophysiological conditions.

Zhu L, Almaça J, Dadi PK, Hong H, Sakamoto W, Rossi M, Lee RJ, Vierra NC, Lu H, Cui Y, McMillin SM, Perry NA, Gurevich VV, Lee A, Kuo B, Leapman RD, Matschinsky FM, Doliba NM, Urs NM, Caron MG, Jacobson DA, Caicedo A, Wess J.

Nat Commun. 2017 Feb 1;8:14295. doi: 10.1038/ncomms14295.

32.

C-terminal motif of human neuropeptide Y4 receptor determines internalization and arrestin recruitment.

Wanka L, Babilon S, Burkert K, Mörl K, Gurevich VV, Beck-Sickinger AG.

Cell Signal. 2017 Jan;29:233-239. doi: 10.1016/j.cellsig.2016.11.003. Epub 2016 Nov 3.

33.

G protein-coupled receptor kinases as regulators of dopamine receptor functions.

Gurevich EV, Gainetdinov RR, Gurevich VV.

Pharmacol Res. 2016 Sep;111:1-16. doi: 10.1016/j.phrs.2016.05.010. Epub 2016 May 10. Review.

34.

Peptide mini-scaffold facilitates JNK3 activation in cells.

Zhan X, Stoy H, Kaoud TS, Perry NA, Chen Q, Perez A, Els-Heindl S, Slagis JV, Iverson TM, Beck-Sickinger AG, Gurevich EV, Dalby KN, Gurevich VV.

Sci Rep. 2016 Feb 12;6:21025. doi: 10.1038/srep21025.

35.

A G Protein-biased Designer G Protein-coupled Receptor Useful for Studying the Physiological Relevance of Gq/11-dependent Signaling Pathways.

Hu J, Stern M, Gimenez LE, Wanka L, Zhu L, Rossi M, Meister J, Inoue A, Beck-Sickinger AG, Gurevich VV, Wess J.

J Biol Chem. 2016 Apr 8;291(15):7809-20. doi: 10.1074/jbc.M115.702282. Epub 2016 Feb 5.

36.

Paradigm Shift is the Normal State of Pharmacology.

Gurevich VV.

EC Pharmacol Toxicol. 2016;2(2):80-85. Epub 2016 Sep 13. No abstract available.

37.

Analyzing the roles of multi-functional proteins in cells: The case of arrestins and GRKs.

Gurevich VV, Gurevich EV.

Crit Rev Biochem Mol Biol. 2015;50(5):440-52. doi: 10.3109/10409238.2015.1067185. Review.

38.

Influence of Arrestin on the Photodecay of Bovine Rhodopsin.

Chatterjee D, Eckert CE, Slavov C, Saxena K, Fürtig B, Sanders CR, Gurevich VV, Wachtveitl J, Schwalbe H.

Angew Chem Int Ed Engl. 2015 Nov 9;54(46):13555-60. doi: 10.1002/anie.201505798. Epub 2015 Sep 18.

39.

Using Bioluminescence Resonance Energy Transfer (BRET) to Characterize Agonist-Induced Arrestin Recruitment to Modified and Unmodified G Protein-Coupled Receptors.

Donthamsetti P, Quejada JR, Javitch JA, Gurevich VV, Lambert NA.

Curr Protoc Pharmacol. 2015 Sep 1;70:2.14.1-14. doi: 10.1002/0471141755.ph0214s70.

40.
41.

Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser.

Kang Y, Zhou XE, Gao X, He Y, Liu W, Ishchenko A, Barty A, White TA, Yefanov O, Han GW, Xu Q, de Waal PW, Ke J, Tan MH, Zhang C, Moeller A, West GM, Pascal BD, Van Eps N, Caro LN, Vishnivetskiy SA, Lee RJ, Suino-Powell KM, Gu X, Pal K, Ma J, Zhi X, Boutet S, Williams GJ, Messerschmidt M, Gati C, Zatsepin NA, Wang D, James D, Basu S, Roy-Chowdhury S, Conrad CE, Coe J, Liu H, Lisova S, Kupitz C, Grotjohann I, Fromme R, Jiang Y, Tan M, Yang H, Li J, Wang M, Zheng Z, Li D, Howe N, Zhao Y, Standfuss J, Diederichs K, Dong Y, Potter CS, Carragher B, Caffrey M, Jiang H, Chapman HN, Spence JC, Fromme P, Weierstall U, Ernst OP, Katritch V, Gurevich VV, Griffin PR, Hubbell WL, Stevens RC, Cherezov V, Melcher K, Xu HE.

Nature. 2015 Jul 30;523(7562):561-7. doi: 10.1038/nature14656. Epub 2015 Jul 22.

42.

Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor.

Chang SD, Mascarella SW, Spangler SM, Gurevich VV, Navarro HA, Carroll FI, Bruchas MR.

Mol Pharmacol. 2015 Sep;88(3):502-11. doi: 10.1124/mol.115.099150. Epub 2015 Jul 1.

43.

G Protein-Coupled Receptor Kinase 2 (GRK2) and 5 (GRK5) Exhibit Selective Phosphorylation of the Neurotensin Receptor in Vitro.

Inagaki S, Ghirlando R, Vishnivetskiy SA, Homan KT, White JF, Tesmer JJ, Gurevich VV, Grisshammer R.

Biochemistry. 2015 Jul 21;54(28):4320-9. doi: 10.1021/acs.biochem.5b00285. Epub 2015 Jul 8.

44.

Arrestins: Critical Players in Trafficking of Many GPCRs.

Gurevich VV, Gurevich EV.

Prog Mol Biol Transl Sci. 2015;132:1-14. doi: 10.1016/bs.pmbts.2015.02.010. Epub 2015 Mar 25. Review.

45.

GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domain.

Ahmed MR, Bychkov E, Li L, Gurevich VV, Gurevich EV.

Sci Rep. 2015 Jun 4;5:10920. doi: 10.1038/srep10920.

46.

C-terminal threonines and serines play distinct roles in the desensitization of rhodopsin, a G protein-coupled receptor.

Azevedo AW, Doan T, Moaven H, Sokal I, Baameur F, Vishnivetskiy SA, Homan KT, Tesmer JJ, Gurevich VV, Chen J, Rieke F.

Elife. 2015 Apr 24;4. doi: 10.7554/eLife.05981.

47.

GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014.

Heifetz A, Schertler GF, Seifert R, Tate CG, Sexton PM, Gurevich VV, Fourmy D, Cherezov V, Marshall FH, Storer RI, Moraes I, Tikhonova IG, Tautermann CS, Hunt P, Ceska T, Hodgson S, Bodkin MJ, Singh S, Law RJ, Biggin PC.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Aug;388(8):883-903. doi: 10.1007/s00210-015-1111-8. Epub 2015 Mar 14.

48.

G Protein-coupled Receptor Kinases of the GRK4 Protein Subfamily Phosphorylate Inactive G Protein-coupled Receptors (GPCRs).

Li L, Homan KT, Vishnivetskiy SA, Manglik A, Tesmer JJ, Gurevich VV, Gurevich EV.

J Biol Chem. 2015 Apr 24;290(17):10775-90. doi: 10.1074/jbc.M115.644773. Epub 2015 Mar 13.

49.

Arrestin-3-Dependent Activation of c-Jun N-Terminal Kinases (JNKs).

Zhan X, Kook S, Kaoud TS, Dalby KN, Gurevich EV, Gurevich VV.

Curr Protoc Pharmacol. 2015 Mar 2;68:2.12.1-2.12.26. doi: 10.1002/0471141755.ph0212s68.

50.

The rhodopsin-arrestin-1 interaction in bicelles.

Chen Q, Vishnivetskiy SA, Zhuang T, Cho MK, Thaker TM, Sanders CR, Gurevich VV, Iverson TM.

Methods Mol Biol. 2015;1271:77-95. doi: 10.1007/978-1-4939-2330-4_6.

Supplemental Content

Loading ...
Support Center